Enpp-1-IN-19

• UNSPSC Description:

  Enpp-1-IN-19 (compound 29f) is an orally active ENPP1 inhibitor that inhibits cGAMP hydrolysis by ENPP1 (IC50=68 nM). Enpp-1-IN-19 increases anti-PD-L1 responses and inhibits tumor growth in CT26 syngeneic models. Enpp-1-IN-19 also enhances STING-mediated type I interferon responses, induces immune memory, and prevents tumor recurrence[1].

• Target Antigen:

  Phosphodiesterase (PDE); STING

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation;Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  cancer

• Assay Protocol:

  https://www.medchemexpress.com/enpp-1-in-19.html

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C1C2=CC=CC=C2C(CC3=CC=C(NS(=O)(N)=O)C=C3)=NN1C

• Molecular Weight:

  344.39

• References & Citations:

  [1]Cho Y et al. Discovery of Orally Bioavailable Phthalazinone Analogues as an ENPP1 Inhibitor for STING-Mediated Cancer Immunotherapy. J Med Chem. 2023 Nov 23;66(22):15141-15170.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  No Development Reported

• CAS Number:

  2738583-25-8